Lipocine (LPCN) announced that the first patient has been dosed in its pivotal Phase 3 clinical trial of LPCN 1154, its investigational oral treatment for postpartum depression. Results are expected in Q2 2026. Following FDA feedback, this study is being conducted in an outpatient setting, with no requirement for medical monitoring by a healthcare provider. The company anticipates using the data from this Phase 3 trial to support an NDA submission of LPCN 1154 for PPD in mid-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
- Lipocine to Host R&D Event on July 9
- Lipocine’s Growth Potential Bolstered by TLANDO’s Canadian Market Entry and Phase 3 Trial for LPCN 1154
- Lipocine announces filing of NDA for TLANDO in Canada
- Lipocine’s Partner Files New Drug Submission in Canada
- Lipocine Approves Key Proposals at Shareholder Meeting